The Americans United for Life blog breaks down how many seats prolifers have in Congress and also notes other races.
Progress using adult stem cells continues. According to the web site of the Scrip World Pharmaceutical News,
Genzyme is to pay Osiris Therapeutics $130 million upfront and up to $1.25 billion in milestones to develop and commercialise two late-stage adult stem cell treatments, Prochymal and Chondrogen, outside the US and Canada.
Prochymal, a preparation of mesenchymal stem cells formulated for intravenous infusion, is currently in two Phase III trials for graft vs host disease, a Phase III trial for Crohn's disease and Phase II trials for type 1 diabetes and chronic obstructive pulmonary disease. Results from the Phase III trials are expected next year and a Phase II trial in acute myocardial infarction is expected to begin soon...